PLB 1004
Alternative Names: PLB-1004Latest Information Update: 16 Sep 2024
At a glance
- Originator Avistone Pharmaceuticals
- Class Aniline compounds; Antineoplastics; Pyrimidines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer
Most Recent Events
- 10 Sep 2024 Efficacy and adverse event data from a phase I/II trial in Non-small cell lung cancer released by Avistone Pharmaceuticals
- 07 Aug 2024 Phase-II clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, First-line therapy) in China (PO) (NCT06574347)
- 01 Jul 2024 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease) in USA (PO) (NCT06046495)